Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed SpA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
Partnerships 12
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
Licensing Agreements 19
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Equity Offering 23
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA – Key Competitors 28
MolMed SpA – Key Employees 29
MolMed SpA – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jul 30, 2018: MolMed approves results at June 30th 2018 31
May 11, 2018: MolMed approves first quarter 2018 results, significantly improved compared to the first quarter 2017 33
Apr 12, 2018: MolMed: the Shareholders’ Meeting approves 2017 Financial Statements 35
Mar 09, 2018: MolMed: Full Year 2017 Results 36
Nov 06, 2017: The Board of Directors Examined the Business Performance and Approved the First Nine Months Financial Report at September 30th, 2017 39
Nov 06, 2017: MolMed Board of Directors examined the business performance and approved the first nine months financial report ended at September 30th, 2017 43
Jul 27, 2017: MolMed Board of Directors reviewed business performance and approved the first half-year financial report ended June 30th, 2017 47
May 08, 2017: MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017 51
Mar 06, 2017: MolMed’s Board of Directors reviewed the business performance and approved the draft financial statements for FY 2016 53
Corporate Communications 57
Sep 24, 2018: MolMed: Carlo Incerti succeeds to Claudio Bordignon as chairman of the board. Salvatore Calabrese appointed officer responsible for the preparation of corporate financial reports 57
Sep 11, 2018: MolMed names Mr. Salvatore Calabrese Chief Financial Officer 59
Jun 29, 2018: MolMed: resignation of the Officer Responsible for the preparation of corporate financial reports 60
Product Approvals 61
Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
MolMed SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Deals By Therapy Area, 2012 to YTD 2018 9
MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11
MolMed Enters into Development Agreement with GlaxoSmithKline 12
MolMed and AbCheck Enter into Agreement 13
Orchard Therapeutics and MolMed Expand Collaboration Agreement 14
MolMed and Cellectis Enter into Co-Development Agreement 15
MolMed Enters into Agreement with Rocket Pharma 16
MolMed Enters into Co-Development Agreement with Genenta Science 17
MolMed Enters into Agreement with GlaxoSmithKline 18
MolMed and Dompe Expand Licensing and Distribution Agreement 19
TTY Biopharm Enters into Licensing Agreement with MolMed 20
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21
Oxford BioMedica Enters into Licensing Agreement with MolMed 22
Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23
MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25
MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27
MolMed SpA, Key Competitors 28
MolMed SpA, Key Employees 29
MolMed SpA, Other Locations 30
List of Figures
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9